|
Oct 16
|
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
|
|
Oct 10
|
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3
|
|
Oct 7
|
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?
|
|
Sep 27
|
3 Stocks That May Be Trading Below Intrinsic Value By Up To 48.2%
|
|
Sep 26
|
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
|
|
Sep 26
|
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
|
|
Sep 25
|
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
|
|
Sep 9
|
BeiGene Announces Updates to Commercial Leadership Team
|
|
Sep 9
|
BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
|
|
Aug 28
|
Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
|
|
Aug 28
|
3 US Stocks That Could Be Trading At A Discount
|
|
Aug 28
|
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Aug 27
|
FDA grants fast track status to BeiGene’s BGB-16673 for CLL/SLL
|
|
Aug 26
|
BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy?
|
|
Aug 26
|
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
|
|
Aug 8
|
Beyond the Balance Sheet: What SWOT Reveals About BeiGene Ltd (BGNE)
|
|
Aug 7
|
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
|
|
Jul 24
|
BeiGene opens biologics facility in New Jersey, US
|
|
Jul 23
|
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
|
|
Jun 27
|
Insider Sale: CFO Julia Wang Sells Shares of BeiGene Ltd (BGNE)
|